Journal
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
Volume 23, Issue 6, Pages 526-532Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0885-3924(02)00391-3
Keywords
olanzapine; cancer; opioid; nausea
Ask authors/readers for more resources
This open-label pilot study explored the antiemetic activity of olanzapine, an atypical antipsychotic, in patients with, advanced cancer requiring, opioid Patients received 2 days of a washout and Placebo run-in followed by two day periods on each of three doses of olanzapine (2.5 mgs, 5 mg and 10 mg). Patients completed, a daily food journal as well (is the Mini Mental Stoic Exam, Simpson Angus Scale, Barnes Akathisia Scale, and the Functional Assessment of Cancer Therapy-General across four time periods, with special attention being placed, on the nausea item. Eleven women and 4 men with varied primary cancer site 5 participated. The average age of the sample was 58 Years (SD) = 16.8). All three dose levels were associated, with significant reductions in nausea compared to baseline. Diary entries recorded by the subjects suggested substantial benefits to overall well being and the 5 mg condition was associated with statistically significant improvement overall quality of life over baseline (F = 12.0, p < 0.005). No were noted and mental status exams were not changed over the course of the eight days. These results suggest an antiemetic effect for olanzapine and indicate the need for a controlled trial. (C) U.S. Cancer Pain Relief Committee, 2002.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available